Response to therapy assessment in intermediate-risk thyroid cancer patients: is thyroglobulin stimulation required?

I Moreno, D Hirsch, H Duskin-Bitan, T Dicker-Cohen… - Thyroid, 2020 - liebertpub.com
Introduction: The 2015 American Thyroid Association (ATA) guidelines recommend
response to therapy (RTT) assessment 1–2 years after initial treatment in differentiated …

Radioiodine refractory differentiated thyroid cancer

Y Jin, D Van Nostrand, L Cheng, M Liu… - Critical reviews in oncology …, 2018 - Elsevier
Differentiated thyroid cancer (DTC) is usually curable with surgery, radioactive iodine (RAI),
and thyroid-stimulating hormone (TSH) suppression. However, local recurrence and/or …

How to better stratify the risk of differentiated thyroid carcinomas: the key role of radioactive iodine therapy, age, and gender

A Piccardo, G Siri, S Raffa, M Castellana… - European journal of …, 2021 - Springer
Purpose The risk of relapse of differentiated thyroid carcinomas (DTC) and their indication
for radioactive iodine therapy (RAI) are assessed according to ATA risk stratification system …

[HTML][HTML] Recurrence incidence in differentiated thyroid cancers and the importance of diagnostic iodine-131 scintigraphy in clinical follow-up

F Hatipoğlu, İ Karapolat, Ö Ömür, A Akgün… - Molecular imaging …, 2016 - ncbi.nlm.nih.gov
Objective: Differentiated thyroid cancers (DTC) are tumors with good prognosis. However,
local recurrence or distant metastasis can be observed. In our study, we aimed to investigate …

Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature

L Lamartina, C Durante, S Filetti… - The Journal of Clinical …, 2015 - academic.oup.com
Background: Radioiodine remnant ablation (RRA) has traditionally been one of the
cornerstones of differentiated thyroid cancer (DTC) treatment. The decision to use RRA in …

[HTML][HTML] Postoperative radioiodine treatment within 9 months from diagnosis significantly reduces the risk of relapse in low-risk differentiated thyroid carcinoma

J Krajewska, M Jarzab, A Kukulska… - Nuclear Medicine and …, 2019 - Springer
Purpose Although postoperative radioiodine (RAI) therapy has been used in patients with
differentiated thyroid carcinoma (DTC) for many years, there is still lack of data defining the …

Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?

C Ma, J Xie, A Kuang - Journal of Nuclear Medicine, 2005 - Soc Nuclear Med
The long-term monitoring of patients with differentiated thyroid carcinoma (DTC) is essential
throughout the patient's life after total or nearly total thyroidectomy followed by 131I remnant …

[HTML][HTML] Outcome of patients with differentiated thyroid cancer treated with 131-iodine on the basis of a detectable serum thyroglobulin level after initial treatment

M Klain, L Pace, E Zampella, T Mannarino… - Frontiers in …, 2019 - frontiersin.org
Background: In patients with differentiated thyroid cancer (DTC) and raising serum
thyroglobulin (Tg) after total or near-total thyroidectomy and 131I remnant ablation an …

[HTML][HTML] The combined evaluation of clinical and biochemical data in management of patients with differentiated thyroid cancer

F Volpe, L Piscopo - European Journal of Nuclear Medicine and …, 2023 - Springer
Differentiated thyroid cancer (DTC) represents the most frequent endocrine neoplasm,
accounting for 5% of thyroid nodules [1]. The standard treatment of patients with DTC …

[HTML][HTML] Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated …

L Giovanella, L Milan, W Roll, M Weber… - European journal of …, 2023 - Springer
Purpose An accurate postoperative assessment is pivotal to inform postoperative 131I
treatment in patients with differentiated thyroid cancer (DTC). We developed a predictive …